Abstract: Objective To study the value of CEA, CYFRA21-1 and TSGF in assessing the curative effect of combined chemotherapy and radiotherapy on advanced non-small cell lung cancer (NSCLC). Methods Fifty-four advanced NSCLC patients admitted to our hospital from January 2009 to January 2012 underwent two cycles of whole body chemotherapy with NVB and DDP followed by stereotactic radiotherapy. Blood samples were taken from the patients before the frst cycle of chemotherapy and 3 month after stereotactic radiotherapy for the measurement of their serum CEA, CYFRA21-1 and TSGF levels. Results Of the 54 patients who received 3 months of combined chemotherapy and radiotherapy, 21 had PR, 18 had SD, and 15 had PD. The serum CYFRA21-1 and TSGF levels and the serum CEA and TSGF levels were signifcantly lower in patients with lung squamous cell carcinoma and in those with lung adenocarcinoma cancer, respectively, after combined chemotherapy and radiotherapy (P＜ 0.01). The serum CEA, CYFRA21-1 and TSGF levels were signifcantly lower in responders than in non- responders (P＜ 0.05) while no signifcant change was observed in non-responders after combined chemotherapy and radiotherapy (P＞ 0.05). Conclusion The serum CEA, CYFRA21-1 and TSGF levels are related with the histopathological type of advanced NSCLC before and after combined chemotherapy and radiotherapy. The curative effect of combined chemotherapy and radiotherapy on advanced NSCLC can thus be assessed by monitoring the serum CEA, CYFRA21-1 and TSGF levels.